Upgrade to SI Premium - Free Trial

Sarepta Therapeutics (SRPT) PT Lowered to $181 at RBC Capital

August 8, 2024 6:27 AM
RBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $181.00 (from $182.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles